1 2 3	BLEICHMAR FONTI & AULD LLP Lesley E. Weaver (Bar No. 191305) 1330 Broadway, Suite 630 Oakland, California 94612 Telephone: (415) 445-4003 Facsimile: (415) 445-4020		
4			
5	Counsel for Lead Plaintiff Martin Dugan and Lead Counsel for the Class		
6	[Additional counsel on signature page]		
7			
8	UNITED STATES 1	DISTRICT C	COURT
9	NORTHERN DISTRI	CT OF CAL	IFORNIA
10			
11	IN RE TALIS BIOMEDICAL SECURITIES LITIGATION	Case No. 2	2-cv-00105-SI
12		CLASS AC	CTION
13	THIS DOCUMENT RELATES TO:	STIPULA' ORDER R	TION AND [PROPOSED] EGARDING
14	ALL ACTIONS	DISSEMINATION OF CLASS NOTICE	
15	ALL ACTIONS	Judge:	Hon. Susan Illston
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			

	1	
	2	
	3	
	4	
	5	
	6	
	7	
	8	
	9	
1	0	
1	1	
1	2	
1	3	
1	4	
1	5	
1	6	
1	7	
1	8	
1	9	
2	0	
2	1	
2	2	
2	3	
2	4	
2	5	
2	6	
2	7	

IT IS HEREBY STIPULATED AND AGREED by Defendants Talis Biomedical Corporation ("Talis"), Brian Coe, J. Roger Moody, Jr., Felix Baker, Raymond Cheong, Melissa Gilliam, Rustem F. Ismagilov, Kimberly J. Popovits, Matthew L. Posard, and Randal Scott (jointly with Talis, "Defendants"), and Lead Plaintiff Martin Dugan ("Plaintiff", collectively with Defendants, the "Parties"), by and through their respective counsel, subject to the Court's approval:

- 1. On February 9, 2024, the Court certified this action as a class action under Rule 23 of the Federal Rules of Civil Procedure (Dkt. No. 153).
 - 2. The Class consists of:

All persons or entities that purchased or otherwise acquired common stock issued by Talis pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby.

Excluded from the Class by definition are:

Excluded from the Class are (i) Defendants and any affiliates or subsidiaries thereof; (ii) present and former officers and directors of Talis and its subsidiaries or affiliates, and their immediate family members (as defined in Item 404 of SEC Regulation S-K, 17 C.F.R. § 229.404, Instructions (1)(a)(iii) & (1)(b)(ii)); (iii) Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; (iv) any entity in which any Defendant has or has had a controlling interest; (v) Talis's employee retirement and benefits plan(s); and (vi) the legal representatives, heirs, estates, agents, successors, or assigns of any person or entity described in the preceding five categories.

- 3. The proposed procedures for giving notice to the Class as set forth in this Stipulation and [Proposed] Order comply with the requirements of due process and with Rule 23 of the Federal Rules of Civil Procedure and constitute the best notice practicable under the circumstances.
- 4. The firm of A.B. Data, Ltd. ("Notice Administrator") is appointed and authorized to supervise and administer the notice procedure.
- 5. Defendant Talis has caused its securities transfer agent to produce a list, in electronic form, of the names and addresses of all persons who purchased or otherwise acquired Talis common stock at any time during the Class Period (the "Transfer List").

25

26

27

28

- 6. No later than thirty (30) days after the Court's approval and entry of this Stipulation and Order (the "Notice Date"), the Notice Administrator shall send, by first class mail, the agreed-upon proposed Notice of Pendency of Class Action (the "Notice"), substantially in the form attached hereto as **Exhibit A**, to each person or entity identified on the Transfer List. For all Notices returned as undeliverable, the Notice Administrator shall use best efforts to locate updated addresses.
- 7. The Notice Administrator shall use reasonable efforts to give notice to nominee purchasers such as brokerage firms and other persons and entities who may have purchased or acquired Talis common stock during the Class Period for the beneficial interest of persons or entities other than themselves. Such nominees shall either (i) within seven (7) calendar days of receipt of the Notice, forward the Notice to all such beneficial owners; or (ii) within seven (7) calendar days of receipt of the Notice, provide a list of the names and addresses of all such beneficial owners to the Notice Administrator, and the Notice Administrator is ordered to send the Notice promptly to such identified beneficial owners. Nominees who elect to send the Notice to their beneficial owners shall send a statement to the Notice Administrator confirming that the mailing was made and shall retain their mailing records for use in connection with any further notices that may be provided in the Action. The Notice Administrator shall follow up with brokers and custodians to ensure the Notice is sent to beneficial owners in a timely manner. Upon full and timely compliance with these directions, such nominees may seek reimbursement of their reasonable expenses actually incurred by providing the Notice Administrator with proper documentation supporting the expenses for which reimbursement is sought. Any disputes with respect to the reasonableness or documentation of expenses incurred shall be subject to review by the Court.
- 8. Contemporaneously with the mailing of the Notice, the Notice Administrator shall establish a website for the Action, www.TalisSecuritiesLitigation.com, from which Class Members may download copies of the Notice, the Long-Form Notice substantially in the form attached hereto as **Exhibit B**, the Summary Notice, the operative Complaint, the Defendants' Answer to the operative Complaint, the Court's order certifying the Class, and this Stipulation and Order. In addition, Class Counsel shall post the Notice, Long-Form Notice, and other documents referenced in the preceding sentence on its website, www.bfalaw.com.

1	9. Within ten (10) business days after the Notice Date, the Notice Administrator shall		
2	cause the Summary Notice, substantially in the form attached hereto as Exhibit C, to be published		
3	in The Wall Street Journal and Investor's Business Daily and to be transmitted over PR Newswire.		
4	10. The Notice shall provide an address for the purpose of receiving requests for		
5	exclusion from the Class and requests for additional copies of the Notice. The requests for		
6	exclusion from the Class shall be made by submitting a written request for exclusion as set fort		
7	in the Notice and shall be postmarked within sixty (60) days after the Notice Date (the "Exclusion		
8	Date").		
9	11. The Notice Administrator shall identify and number all exclusion requests received		
10	and create copies of those requests for counsel for all parties. The Notice Administrator shall		
11	provide via email weekly reports of exclusion requests received to counsel for all parties. The		
12	Notice Administrator will maintain original requests in its files.		
13	12. No later than fifteen (15) business days after the Exclusion Date, Class Counsel		
14	shall file with the Court proof of mailing of the Notice, proof of publication of the Summary		
15	Notice, and an affidavit setting forth a list of all persons and entities who have requested exclusion		
16	from the Class.		
17	13. The costs of the notice process shall be borne by the Class Representative, and not		
18	by Defendants, subject to reimbursement from any settlement or other recovery.		
19	14. This Order may be modified by the Court upon motion by either or both parties, for		
20	good cause shown.		
21	IT IS SO STIPULATED, THROUGH COUNSEL OF RECORD.		
22			
23			
24			
25			
26			
27			
28			

1	Dated: May 21, 2024	
2	By: /s/ Joseph A. Fonti	By: /s/ Patrick E. Gibbs
3		•
4	BLEICHMAR FONTI & AULD LLP Joseph A. Fonti (pro hac vice)	COOLEY LLP Patrick E. Gibbs (Bar No. 183174)
5	jfonti@bfalaw.com Evan A. Kubota (<i>pro hac vice</i>)	Shannon M. Eagan (Bar No. 212830) Jessie Simpson LaGoy (Bar No. 305257)
6	ekubota@bfalaw.com 300 Park Avenue, Suite 1301	3175 Hanover Street Palo Alto, California 94304
7	New York, New York 10022 Tel: (212) 789-1340	Telephone: (650) 843-5000 Facsimile: (650) 849-7400
	Fax: (212) 205-3960	pgibbs@cooley.com
8	– and –	seagan@cooley.com jsimpsonlagoy@cooley.com
9	Lesley E. Weaver (Bar No. 191305)	– and –
10	lweaver@bfalaw.com 1330 Broadway, Suite 630	Zachary Sisko (pro hac vice)
11	Oakland, California 94612	500 Boylston Street 14th Floor
12	Tel.: (415) 445-4003 Fax: (415) 445-4020	Boston, Massachusetts 02116-3736
13	Counsel for Lead Plaintiff Martin Dugan and	Telephone: +1 617 937 2300 Facsimile: +1 617 937 2400
14	Lead Counsel for the Class	zsisko@cooley.com
15	THE SCHALL LAW FIRM Brian Schall (Bar No. 290685)	Attorneys for Defendants Talis Biomedical Corporation, Brian Coe, J. Roger Moody, Jr.,
16	2049 Century Park East, Suite 2460	Felix Baker, Raymond Cheong, Melissa
	Los Angeles, California 90067 Telephone: (424) 303-1964	Gilliam, Rustem F. Ismagilov, Kimberly J. Popovits, Matthew L. Posard, and Randal Scott
17	brian@schallfirm.com	
18	Additional Counsel for Lead Plaintiff Martin Dugan	
19	POMERANTZ LLP	
20	Jennifer Pafiti (Bar No. 282790)	
21	1100 Glendon Avenue, 15th Floor Los Angeles, California 90024	
22	Telephone: (310) 405-7190 Facsimile: (212) 661-8665	
23	jpafiti@pomlaw.com	
24	Jeremy A. Lieberman (<i>pro hac vice</i> application forthcoming)	
	J. Alexander Hood II (pro hac vice)	
25	James M. LoPiano (pro hac vice) Jonathan D. Park (pro hac vice)	
26	600 Third Avenue, 20th Floor New York, New York 10016	
27	Telephone: (212) 661-1100 Facsimile: (212) 661-8665	
28	jalieberman@pomlaw.com	

Case 3:22-cv-00105-SI Document 166 Filed 05/22/24 Page 6 of 15

1 2	ahood@pomlaw.com jlopiano@pomlaw.com jpark@pomlaw.com
3	Additional Counsel for the Class
4	
5	
6	<u>ATTESTATION</u>
7	Pursuant to Civil L.R. 5-1(i)(3), I, Joseph A. Fonti, hereby attest that the concurrence to
8	the filing of the foregoing document has been obtained from the signatories.
9	Dated: May 21, 2024 /s/ Joseph A. Fonti Joseph A. Fonti
10	Joseph A. Politi
11	
12	
13	
14	PURSUANT TO THE STIPULATION, IT IS SO ORDERED.
15	O AA
16	Dated: May 22 , 2024
17	The Honorable Susan Illston United States District Judge
18	
19	
20	
21	
22 23	
23 24	
25	
26	
27	
28	

Case 3:22-cv-00105-SI Document 166 Filed 05/22/24 Page 7 of 15 $\mathbf{EXHIBIT}$ \mathbf{A}

In re Talis Biomedical Corporation Securities Litigation, Case No. 22-cv-00105-SI (N.D. Cal.) FOR MORE INFORMATION PLEASE VISIT www.TalisSecuritiesLitigation.com or call 877-331-0411

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Northern District of California that the above-captioned action (the "Action") has been certified to proceed as a class action against Defendant Talis Biomedical Corporation ("Talis") and certain current and former officers and directors ("Defendants"). IF YOU ARE A CLASS MEMBER, YOUR RIGHTS WILL BE AFFECTED BY THIS CLASS ACTION LAWSUIT. This postcard advises you of information about your options. A long-form Notice with further information about your rights is available at the case website above or by calling the telephone number listed above.

Who is included in the Class? All persons or entities that purchased or otherwise acquired common stock issued by Falls pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby.

Excluded from the Class are (i) Defendants and any affiliates or subsidiaries thereof, (ii) present and former officers and directors of Talis and its subsidiaries or affiliates, and their immediate family members (as defined in Item 404 of SEC Regulation S-K, 17 C.F.R. § 229.404, Instructions (1)(a)(iii) & (1)(b)(ii)); (iii) Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; (iv) any entity in which any Defendant has or has had a controlling interest; (v) Talis's employee retirement and benefits plan(s); and (vi) the legal representatives, heirs, estates, agents, successors, or assigns of any person or entity described in the preceding five categories.

What are my options? This class action is still being litigated and no money has yet been recovered. If you do nothing, you will remain a member of the Class and, if there is a future recovery or settlement, you may be eligible for a payment. If you remain a Class Member, you will be bound by the proceedings in this Action, including all past, present, and future orders and judgments of the Court, whether favorable or unfavorable, and you may not pursue your own lawsuit with regard to any of the issues in this Action.

If you DO NOT want to remain a Class Member and be legally bound by anything that happens in this case, you must exclude yourself from the Class. To exclude yourself, you must submit a request in writing by no later than ______, 2024, pursuant to the instructions in the long-form Notice available at www.TalisSecuritiesLitigation.com. If you choose to exclude yourself, you will not be able to receive any money from this Action, but you will be entitled to pursue any individual remedy that you may have, at your own expense. You may contact the Administrator or Class Counsel with any questions. Please note, if you decide to exclude yourself from the Class, you may be time-barred from asserting the claims covered by the Action.

What has happened so far? This case began on January 7, 2022, and alleges claims under Sections 11 and 15 of the Securities Act of 1933. The Class Representative alleges that the Defendants made false and misleading statements and material omissions concerning Talis One. Defendants deny all of these allegations, and deny any wrongdoing or violation of law. In April 2023, the Court denied Defendants' motion to dismiss the case. In February 2024, the Court certified the above-referenced Class and appointed Martin Dugan as Class Representative and Bleichmar Fonti & Auld LLP and Pomerantz LLP as Co-Class Counsel. The parties have conducted substantial discovery, and no trial date has been set.

<u>Your Other Rights</u>. Class Members are represented by Class Counsel. You will not be personally responsible for their fees and expenses. You may also hire your own attorney, at your own expense, and, if you do so, they must file a notice of appearance with the Court.

Please keep your investment records concerning Talis and notify the administrator of any change of address.

For more information, call 877-331-0411, send an email to info@TalisSecuritiesLitigation.com, or visit www.TalisSecuritiesLitigation.com. Do not contact the Court, Defendants, or their counsel in this Action with questions.

EXHIBIT B

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

In re Talis Biomedical Corporation Securities Litigation Case No. 22-cv-00105-SI

NOTICE OF PENDENCY OF CLASS ACTION

TO: All persons or entities that purchased or otherwise acquired common stock issued by Talis pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby.

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

You have received notice because your rights may be affected by a class action lawsuit regarding your purchase or acquisition of publicly-traded common stock of Talis Biomedical Corporation ("Talis" or the "Company"). If you are a Class Member, your rights will be affected by this lawsuit, which is referred to as *In re Talis Biomedical Corporation Securities Litigation*, Case No. 22-cv-00105-SI (the "Action"), and which is now pending before the United States District Court for the Northern District of California (the "Court"). The Court has ordered this notice to be sent to you.

On February 9, 2024, the Court determined that this lawsuit may proceed as a class action pursuant to Rule 23 of the Federal Rules of Civil Procedure. The purpose of this Notice is to inform you how the lawsuit may affect your rights and what steps you may take. This Notice is not an expression by the Court of any opinion as to the merits of any of the claims or defenses asserted by either side in the lawsuit. If you received notice in error and you are not a member of the Class, you do not need to take any action and your rights will not be affected.

WHAT ARE MY OPTIONS?		
Do Nothing	Stay in this lawsuit. Await the outcome. Give up certain rights.	
	By doing nothing, you keep the possibility of sharing in any recovery that may result from trial or settlement. But you give up any right you may have to sue the Defendants separately about the issues and claims being raised in this lawsuit, and you will be bound by the outcome of the case.	
Ask to be excluded by . 2024	uded by Get out of the lawsuit. Get no benefits from the lawsuit. Keep your rights.	
, 2024	If you ask to be excluded from the lawsuit, you will not be bound by what the Court does in this case and will keep any right you might have to sue Defendants separately about the same issues and claims being raised in this lawsuit. If a	

recovery is later awarded in this case, you would not share in that recovery. Please note, if you decide to exclude yourself from the Class, you may be timebarred from asserting the claims covered by the Action.
barred from asserting the claims covered by the Action.

1. WHAT IS THIS LAWSUIT ABOUT?

This is a securities lawsuit filed in the United States District Court for the Northern District of California. The operative Amended Complaint in the Action names as defendants Talis; Brian Coe, Talis's co-founder and former President, Chief Executive Officer, and Board member; J. Roger Moody, Jr., Talis's former Chief Financial Officer; and current and former Board members Felix Baker, Raymond Cheong, Melissa Gilliam, Rustem F. Ismagilov, Kimberly J. Popovits, Matthew L. Posard, and Randal Scott. The Court appointed Lead Plaintiff Martin Dugan as Class Representative in this lawsuit.

(a) THE CLASS REPRESENTATIVE'S CLAIMS

The Class Representative, on behalf of the Class, alleges that Defendants violated Sections 11 and 15 of the Securities Act of 1933 based on materially false and misleading statements and omissions in the Registration Statement for Talis's February 11, 2021 initial public offering. The Class Representative alleges that Defendants made false and misleading statements and material omissions about Talis One, the Company's molecular diagnostic platform designed to test for COVID-19 and other diseases at the point of care. Specifically, the Amended Complaint alleges Defendants made misstatements about the ordering and manufacturing of Talis One instruments and Talis One's accuracy and reliability, as well as material omissions about the weakness of Talis's comparator assay and Talis One's unreliability.

(b) DEFENDANTS' DENIAL OF LIABILITY

Defendants deny all of these allegations, any wrongdoing or violation of law, and any and all liability under Sections 11 and 15 of the Securities Act of 1933.

2. WHO IS A CLASS MEMBER?

By order dated February 9, 2024, the Court certified the following Class of plaintiffs:

All persons or entities that purchased or otherwise acquired common stock issued by Talis pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby.

Excluded from the Class by definition are:

Excluded from the Class are (i) Defendants and any affiliates or subsidiaries thereof; (ii) present and former officers and directors of Talis and its subsidiaries or affiliates, and their immediate family members (as defined in Item 404 of SEC Regulation S-K, 17 C.F.R. § 229.404, Instructions (1)(a)(iii) & (1)(b)(ii)); (iii) Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; (iv) any entity in which any Defendant has or has had a controlling interest; (v) Talis's employee retirement and benefits plan(s); and (vi) the legal representatives, heirs, estates, agents, successors, or assigns of any person or entity described in the preceding five categories.

The ruling by the Court certifying the Class does not address the merits of this litigation. Rather, the certification of the Class means only that the ultimate outcome of the Action—whether favorable or unfavorable to the Class—will apply in like manner to each Class Member who does not timely elect to be excluded from the Class.

3. WHO REPRESENTS THE CLASS?

The Court appointed the law firms Bleichmar Fonti & Auld LLP and Pomerantz LLP as Co-Class Counsel to represent the Class in this lawsuit. Class Counsel may be contacted at the addresses and phone numbers listed below under Question 6.

4. How Do You Participate In This Class Action?

If you fall within the definition of the Class set forth above, you are a member of the Class. IF YOU WISH TO REMAIN A MEMBER OF THE CLASS, YOU DO NOT NEED TO DO ANYTHING AT THIS TIME. As a Class Member, you will be bound by any judgment or settlement, whether favorable or unfavorable, in this Action. Thus, you may participate in any monetary settlement or judgment rendered in favor of the Class, and you may submit a Proof of Claim following such a settlement or judgment. This case is ongoing and no settlement or judgment has occurred at this time. You will also be bound by any unfavorable judgment which may be rendered in favor of Defendants. You will not necessarily have the further opportunity to seek exclusion from the Class at the time of any settlement. It is within the Court's discretion whether to allow a second opportunity to request exclusion from the Class if the Action is resolved by a settlement. In other words, this may be your only chance to opt out of the Class.

The Class Representative and Class Counsel represent the Class and all of its members. Class Counsel has agreed to pursue this Action on a contingent-fee basis. All attorney's fees and expenses will be payable only out of a recovery by the Class, if any, and will be subject to approval by the Court. Class Members will not have to pay lawyers any additional amounts, and in no event will individual Class Members be obligated to pay any judgment, court costs, or lawyer's fees for participating in this Action.

Any Class Member who does not request exclusion from the Class may also enter an appearance through his or her own counsel at his or her own expense.

Members of the Class will be eligible to participate in any recovery that might be obtained in the Action. While this Notice is not intended to suggest any likelihood that members of the Class will recover any money, should there be a recovery, Class Members will be advised on how to submit a claim and required to submit a Proof of Claim documenting their sales, purchases, and/or holdings of Talis common stock. For this reason, please be sure to keep all records of your transactions and holdings in Talis common stock. DO NOT mail them to Class Counsel or the Notice Administrator at this time. No money or benefits are available now and there is no guarantee that any money or benefits will be obtained.

5. How Can You BE EXCLUDED FROM THE CLASS?

If you wish to be excluded from the Class, meaning to opt out of the lawsuit, you must submit a request for exclusion in accordance with the instructions in the next paragraph. If you choose to be excluded: (1) you will NOT be entitled to share in any recovery from any settlement or judgment that may be paid to members of the Class as a result of a trial or other resolution of this lawsuit; (2) you will NOT be bound by any judgment or release entered in this lawsuit; and (3) at your own expense, you MAY pursue any claims that you have by filing your own lawsuit or taking other action.

To exclude yourself from the Class, you must submit a written request via email or mail stating that you

"request exclusion from the Class in *In re Talis Biomedical Corporation Securities Litigation*, Case No. 22-cv-00105-SI." Your request must: (i) state the name, address, and telephone number of the person or entity requesting exclusion, and, in the case of entities, the name and telephone number of the appropriate contact person; and (ii) be signed by the person or entity requesting exclusion or an authorized representative, accompanied by proof of authorization. You must submit your exclusion request to the Notice Administrator, A.B. Data, Ltd., *by* ______, *2024* either by email to <u>info@TalisSecuritiesLitigation.com</u> or by mail at the following address:

Talis Securities Litigation EXCLUSIONS c/o A.B. Data, Ltd. PO Box 173001 Milwaukee, WI 53217

Only request exclusion if you do NOT wish to participate in the Class Action and do NOT wish to share in any potential recovery that the Class may obtain.

If you are excluded and pursue your own individual action you may have to produce information and/or documents upon the Defendants' request (a process known as "discovery"), which could include, but not be limited to, providing testimony under oath. You may also be time-barred from asserting the claims covered by the Action.

6. How Can You Get More Information?

This Notice contains only a summary of the litigation and your rights as a potential Class Member. For more detailed information regarding the matters involved in this litigation, please refer to the papers on file in this Action, which may be inspected, during business hours, at the Office of the Clerk of Court, 450 Golden Gate Ave., San Francisco, CA 94102. In addition, important documents in the case have been posted on the following website: www.TalisSecuritiesLitigation.com. Inquiries regarding this litigation may also be made to the following Class Counsel:

Evan A. Kubota

BLEICHMAR FONTI & AULD LLP

300 Park Avenue, Suite 1301 New York, NY 10022 1-888-879-9418

7. CHANGE IN YOUR ADDRESS.

If this Notice was mailed to you at an old address, or if you move, please advise the Notice Administrator of your current address so that you can receive any future notice and/or Proof of Claim forms. The Notice Administrator can be reached at *Talis Securities Litigation*, c/o A.B. Data, Ltd., PO Box 173064, Milwaukee, WI 53217 or by phone at 877-331-0411 or by email at info@TalisSecuritiesLitigation.com. If you are not a member of the Class, you may discard this notice.

8. NOTICE TO BROKERS AND CUSTODIANS.

If, during the period from February 11, 2021 and August 11, 2021, inclusive, you purchased or otherwise acquired Talis stock for the beneficial interest of persons or organizations other than yourself, you must either: (i) within seven (7) calendar days of receipt of the Notice, forward the Notice to the beneficial owners; or (ii) within seven (7) calendar days of receipt of this Notice, provide a list of the names and addresses of

all such beneficial owners to the Notice Administrator at *Talis Securities Litigation*, c/o A.B. Data, Ltd., PO Box 173064, Milwaukee, WI 53217 or by email at info@TalisSecuritiesLitigation.com.

If you choose the first option, you must send a statement to the Administrator confirming that you sent notice to the beneficial owners and you must retain your records for use in connection with any further notices that may be provided in the Action. If you choose the second option, the Administrator will send a copy of the Notice to the beneficial owners. Upon full and timely compliance with these directions, such nominees may seek reimbursement of their reasonable expenses actually incurred by providing the Notice Administrator with proper documentation supporting the expenses for which reimbursement is sought. Copies of this Notice may also be obtained from www.TalisSecuritiesLitigation.com, or by calling the Notice Administrator toll free at 877-331-0411.

DATED:	,	2024.
--------	---	-------

BY ORDER OF THE COURT:
Judge Susan Illston
United States District Judge
United States District Court for the
Northern District of California

EXHIBIT C

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

In re Talis Biomedical Corporation Securities Litigation

Case No. 22-cv-00105-SI

SUMMARY NOTICE OF PENDENCY OF CLASS ACTION

To: All persons or entities that purchased or otherwise acquired common stock issued by Talis pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Northern District of California that the above-captioned action (the "Action") has been certified to proceed as a class action on behalf of the Class as defined above.

The Action alleges that Defendants Talis Biomedical Corporation ("Talis") and certain of its current and former officers and directors ("Defendants") made false and misleading statements and material omissions concerning Talis One in violation of the Securities Act of 1933. Defendants deny all of these allegations, and deny any wrongdoing or violation of law. <u>Please note</u>: at this time, there is no judgment, settlement, or monetary recovery.

IF YOU ARE A MEMBER OF THE CLASS, YOUR RIGHTS WILL BE AFFECTED BY THIS ACTION. Additional information about the Action and access to important documents, including, but not limited to, a long-form Notice of Pendency of Class Action that more fully sets forth your rights in this Action, the operative pleadings, and the Court Order certifying the above-referenced Class, is available at www.TalisSecuritiesLitigation.com or by contacting the Notice Administrator at:

Talis Biomedical Corporation Securities Litigation c/o A.B. Data, Ltd., PO Box 173064 Milwaukee, WI 53217 877-331-0411 info@TalisSecuritiesLitigation.com

Inquiries may also be made to the following representatives of Class Counsel:

Evan A. Kubota **BLEICHMAR FONTI & AULD LLP**

300 Park Avenue, Suite 1301 New York, NY 10022 1-888-879-9418

If you are a Class Member, you have the right to decide whether to remain a member of the Class. If you want to remain a member of the Class, you do not need to do anything at this time other than to retain your documentation reflecting your transactions and holdings in Talis common stock. Pursuant to Federal Rule of Civil Procedure 23(c)(3), if you are a Class Member and do not exclude yourself from the Class, you will be bound by the proceedings in this Action, including all past, present, and future orders and judgments of the Court, whether favorable or unfavorable.

If you ask to be excluded from the Class, you will not be bound by any order or judgment of this Court in this Action; however, you will not be eligible to receive a share of any money which might be recovered for the benefit of the Class. To exclude yourself from the Class, you must submit a written request for exclusion by *no later than* ______, 2024, in accordance with the instructions set forth in the long-form Notice available at www.TalisSecuritiesLitigation.com.

Further information regarding this Notice may be obtained by visiting the case website above.

PLEASE DO NOT CONTACT THE COURT REGARDING THIS NOTICE.

BY ORDER OF THE COURT: Judge Susan Illston United States District Judge United States District Court for the Northern District of California